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The incidence of asthma and allergy has
increased during the past decades; this increase
is considered to be caused by environmental
exposure rather than genetic factors (Beasley
et al. 2003; Selgrade et al. 2006). However,
the mechanisms activated in exposed respira-
tory cells and tissues, as well as the causative
particulate constituents and sources, remain to
be clarified. In several epidemiologic studies
the use of polyvinyl chloride (PVC) materials
in indoor environments has been associated
with an increased risk of asthma and allergy. It
has been proposed that the plasticizer used in
PVC carpets, diethylhexyl phthalate (DEHP),
which binds onto the surface of building
materials, may lead to the formation of sub-
stantial amounts of inhalable particles
contaminated with agents of PVC origin (Øie
et al. 1997). Recently, DEHP concentrations
were found to be higher in buildings erected
before 1960 (Bornehag et al. 2005a). This
could reﬂect the higher fractional concentra-
tions in older products or the higher emission
rates as these products degrade.
Thus, plastic building materials are poten-
tial chemical emission sources in indoor air.
These emissions can cause inﬂammation and
subsequently lead to an increased risk of
asthma. This hypothesis is supported by
studies on nasal, conjunctival, and asthmatic
symptoms in relation to building dampness
and the degradation of PVC ﬂooring material
(Norbäck et al. 2000; Wieslander et al.1999).
These studies have shown that the degrada-
tion of DEHP from PVC ﬂooring evokes con-
junctival and nasal irritation and increases
asthma-like symptoms in the exposed subjects.
Furthermore, one PVC degradation product,
2-ethylhexanol, was detected in indoor air
samples. Studies in young children have also
revealed an association between the chemical
emissions of PVC materials into indoor air
and adverse respiratory effects (Jaakkola et al.
1999, 2000). In addition, Bornehag et al.
(2004) reported that there was a dose–
response relationship between asthma preva-
lence in children and the concentrations of
DEHP in settled dust in their environments.
The combination of water leakage and PVC
as ﬂooring material was also shown to be asso-
ciated with a higher prevalence of airway,
nasal, and dermal symptoms in exposed
children (Bornehag et al. 2005b). 
Jaakkola et al. (1999) and Øie et al.
(1997) proposed that phthalate esters act as
either allergens or adjuvants; although there
does seem to be a clear association between
health problems and PVC materials, the
etiologic factors behind this link are still
unclear. In the present study, 10 subjects
exposed to degrading PCV products at their
workplace were challenged by PVC under
controlled conditions. We have previously
reported the renovation work being carried
out in the building (Tuomainen et al. 2004). 
Materials and Methods
Subjects. Ten volunteer subjects (seven males,
three females) provided their written informed
consent prior to the study. The mean age of
the subjects was 43.2 years (range, 28–53
years). There were two current smokers and
two ex-smokers among the subjects, and the
others had never smoked. Smoking was pro-
hibited during the study periods. Five subjects
had doctor-diagnosed asthma, three of them
having received this diagnosis during occupa-
tional exposure to degraded PVC flooring
material. The subjects were asked not to use
inhaled steroids, long-acting β2-adrenoreceptor
agonists, leukotriene receptor antagonists, or
mast cell stabilizers for 3 days before the chal-
lenges or short-acting β2-adrenoreceptor ago-
nists for 6 hr before the challenges. The ﬁve
non-asthmatic subjects also presented with a
variety of symptoms: upper and lower respira-
tory tract symptoms, conjunctival irritation,
and eczema. All of the subjects worked in a
building where the initial indoor air evalua-
tions were made in 1997; the source of the
symptoms in the occupants was later traced to
degrading PVC ﬂooring materials, as described
previously (Tuomainen et al. 2004).
The study was approved by the ethics
committee of Helsinki University Hospital,
which guarantees that approved studies fulﬁll
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BACKGROUND: Polyvinyl chloride (PVC) materials have been linked to asthma in several epidemio-
logic studies, but the possible causal factors remain unknown.
PARTICIPANTS: We challenged 10 subjects experimentally to degraded PVC products under con-
trolled conditions. All of the subjects had previously experienced respiratory symptoms suspected to
be caused by this kind of exposure in their work place. Five subjects had doctor-diagnosed asthma.
METHODS: The subjects were exposed to degraded PVC material in an exposure chamber; a chal-
lenge with ceramic tile was used as the control test. We followed exhaled nitric oxide, nasal NO,
lung functions, cytokines [tumor necrosis factor-α (TNF-α), interleukin-4 (IL-4), IL-6, and IL-12]
and NO in nasal lavage fluid (NAL) during and after the exposures. We also measured 2-ethyl-
hexanol in exhaled breath samples and NAL.
RESULTS: On the morning after the PVC exposure, subjects reported respiratory tract symptoms
signiﬁcantly more often than they did after the control test (50% vs. 0%, respectively; p = 0.029;
n = 10). We did not detect any changes in lung functions or levels of exhaled NO, nasal NO, or
NO in NAL after PVC challenge compared with the control test. Cytokine levels increased after
both exposures, with no statistically significant difference between situations. All of the exhaled
breath samples collected during the PVC exposure contained 2-ethylhexanol.
CONCLUSIONS: PVC ﬂooring challenge can evoke respiratory tract symptoms in exposed subjects.
Our results do not support the hypothesis that PVC materials themselves evoke immediate asthmatic
reactions. The chamber test used is well suited to this type of exposure study.
KEY WORDS: asthma, chamber exposure, cytokine, nitric oxide, PVC flooring material. Environ
Health Perspect 114:1409–1413 (2006). doi:10.1289/ehp.8965 available via http://dx.doi.org/
[Online 18 May 2006]the requirements of international regulations.
We conducted this study according to princi-
ples of the Declaration of Helsinki (World
Medical Association 2004).
Chamber exposure tests. The exposure
chamber (1.2 × 1.2 × 2.2 m) was constructed
of stainless steel and was equipped with a
small window. The chamber had separate
ventilation that was adjusted so the carbon
dioxide concentration stayed < 1,000 ppm
during the exposure session. Before conduct-
ing the experiments, we tested the chamber
and determined that it was sealed properly
and clean [total volatile organic compounds
(TVOCs) < 10 μg/m3]. The material used in
the exposure tests was a 1-m2 piece of PVC
flooring material recently removed from an
ofﬁce where the occupants had suffered respi-
ratory and dermal irritation symptoms related
to degrading PVC. The piece of PVC ﬂooring
material was replaced every week. During the
control tests, we placed unused 1-m2 ceramic
tiles in the chamber ﬂoor. During every PVC
exposure test, we measured TVOC and
2-ethylhexanol concentrations in the chamber
air (Tuomainen et al. 2004). 
Two hours after the beginning of the
exposure, we collected and analyzed VOCs
from the chamber air and from the exhaled
breath into laminate bags as described previ-
ously (Tuomainen et al. 2001). Similar lami-
nate bags have been used in collecting air
samples such as sulfur oxides, and the bags do
not release any emissions themselves. In the
chamber, the sample was always collected
near the breathing zone of the test subject.
We measured concentrations of TVOCs and
2-ethylhexanol in each sample.
The protocol of the chamber challenge
tests is shown in Table 1. The challenges lasted
4 hr, during which the subject remained in the
chamber. We performed PVC and control
exposures in a random order, and the subjects
were blinded to the type of exposure. The
interval between the two exposures ranged
from 3 to 7 weeks. 
Lung function tests. We measured stan-
dard spirometric values according to American
Thoracic Society guidelines (American
Thoracic Society 1991), and we used reference
values of Viljanen et al. (1982) for the Finnish
population. We recorded spirometric and
peak expiratory ﬂow (PEF) values during and
after the exposures (Table 1). 
Measurement of exhaled and nasal NO.
We measured exhaled nitric oxide with a
chemiluminescence analyzer (Sievers Model
280 NOA; Sievers Instruments Inc., Boulder,
CO, USA) according to American Thoracic
Society recommendations (American Thoracic
Society 1999). During measurement of
exhaled NO, the subjects performed a slow
vital capacity maneuver for 30 sec against a
ﬁxed expiratory resistance. We optimized the
pressure level during exhalation by following
online via the computer screen so that the sub-
jects could achieve a constant flow rate in
exhaled air. Exhaled air was led through a non-
breathing valve into a Teflon tubing system
connected to the analyzer. We performed the
recordings using the single-breath program,
and observed measurements on the computer
screen during the tests. The relative SD
between three exhaled samples was expected to
be < 10%, and the detection limit for NO was
1 ppb. Measurements were performed in the
same laboratory under the same conditions.
The chemiluminescence analyzer was cali-
brated daily by using zero air and a certified
concentration of NO.
When measuring nasal NO levels, we
used a modiﬁcation of the ﬁxed-ﬂow exhala-
tion technique of Stark et al. (2005). Two
soft well-ﬁtting nose pieces were placed at the
entrance of both nostrils. The pieces were
attached via a “Y” connector to a two-way
valve, and a resistor was placed in the exhala-
tion limb, which required a pressure of 10 cm
H2O to produce a flow of 100 mL/sec. The
subjects inhaled normal room temperature air
to total lung capacity (TLC) via their mouths
and exhaled nasally, while targeting a ﬂow sig-
nal displayed on the computer monitor. The
expiration was continued until a steady NO
plateau lasting at least 10 sec was reached.
The contribution of any oral NO was
excluded. The measurement was repeated
3 times, and the mean value was calculated.
The measurement schedule of exhaled
and nasal NO during and after the exposures
is shown in Table 1.
Nasal lavage. We collected the nasal lavage
ﬂuid (NAL) samples according to the protocol
described by Hirvonen et al. (1999) with some
modifications. First, 4.5 mL prewarmed
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Table 1. Protocol used in the chamber exposure
tests for PVC and control. 
Time Protocol
Before the exposure Exhaled and nasal NO
Spirometry
PEF
Collection of NAL
Exposure (4 hr) PEF at 1-hr intervals
Exhaled breath sample (after
2 hr from the beginning of
exposure, only in PVC exposure)
Collection of VOC from the
chamber air (sampling time 2 hr)
Immediately after Exhaled and nasal NO
the exposure Spirometry
PEF
Collection of NAL 
2 hr after the  Exhaled and nasal NO
exposure Spirometry
PEF
Next morning after Exhaled and nasal NO
the exposure Spirometry
PEF
PEF, peak expiratory ﬂow.
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Figure 1. Concentrations of TVOCs and 2-ethylhexanol during the PVC exposure and TVOCs during the con-
trol (ceramic tile) test in exposure chamber air.
Figure 2. Correlation between TVOCs in exposure
chamber air and in exhaled breath samples during
exposure to PVC. R2 = 0.84.
Figure 3. Correlation between 2-ethylhexanol con-
centrations in exposure chamber air and in exhaled
breath samples during exposure to PVC. R2 = 0.4792.Hanks’ balanced salt solution (37°C) was
instilled through a heat-softened catheter into
the subject’s nostril. During the instillation,
the subject held his or her chin down toward
the chest and held the catheter in place by
pinching the nostrils closed. The cartilaginous
bridge of the nose was vibrated with a neonatal
percussor (Neo-Cussor, General Physiotherapy
Inc., St. Louis, MO, USA) while the fluid
was refluxed three times. Subsequently, we
repeated the same protocol on the other
nostril. The sample was centrifuged (425 × g,
10 min) and the cells were resuspended in
2 mL of the supernatant. The remaining cell
suspension was incubated for 24 hr at 37°C
and then centrifuged (425 × g, 10 min). The
supernatant and cells were frozen at –70°C.
Analysis of cytokines, NO, protein, and
2-ethylhexanol in NAL. We analyzed the con-
centrations of tumor necrosis factor-α
(TNF-α), interleukin-4 (IL-4), IL-6, and
IL-12 in the NAL supernatant using enzyme-
linked immunosorbent assay (ELISA) kits
(R&D Systems, Minneapolis, MN, USA).
Assays were performed according to the manu-
facturer’s instructions and analyzed with an
ELISA microplate reader (iEMS Reader MF,
Labsystems, Helsinki, Finland) at a wavelength
of 450 nm by comparing the absorbances of
the samples to the standard curve. Each stan-
dard and sample was run in duplicate. The
concentration of NO in the NAL supernatant
was assayed by the Griess reaction as the stable
NO oxidation product nitrite (Green et al.
1982) as described in detail by Hirvonen et al.
(1999). We collected the NAL samples for
cytokine and NO determinations before and
immediately after the exposures (Table 1). In
addition to exposure tests, we measured
cytokine and NO concentrations in NAL after
each subject had at least a 1 week holiday
from work. 
A portion of the NAL was centrifuged at
1,800 rpm (10 min), after which 200 μL was
separated into an Eppendorf tube for protein
measurement; this sample, as well as the rest of
the supernatant, were stored at –18°C before
the analysis of proteins and assay of 2-ethyl-
hexanol. We measured the protein content of
the samples in a microplate reader using the
method of Bradford (1976). 2-Ethylhexanol
present in the NAL was extracted with ethyl
acetate and analyzed by gas chromatography
and mass spectrometry.
Cytospin. Cytocentrifuge preparations
were made from the NAL samples using
100 μL resuspended cell suspension, in which
the mucus had been broken by addition of
0.5% dithiothreitol/0.1% bovine serum albu-
min. The solution was centrifuged, cells were
placed on slides, and the slides were stained
with May-Grunwald-Giemsa stain (Prat et al.
1993) for the cell differential counts. 
Symptoms related to the exposures. The
subjects were asked to report respiratory or any
other symptoms during both PVC and control
exposure sessions, as well as the morning after
the tests. The subjects wrote down their symp-
toms in the PEF follow-up questionnaire.
Statistical methods. We evaluated the
changes in different parameters during and
after the exposures using variance analysis of
repeated measures. Logarithmic transforma-
tions were performed for data not normally
distributed. Between-groups differences were
analyzed by the Fisher’s exact test. We used the
Pearson’s test to determine correlations, and
we compared percentages using the chi-square
test. SPSS for Windows 11.5 (SPSS Inc.,
Chicago, IL, USA) was used in the analysis of
the data; p < 0.05 was considered statistically
signiﬁcant.
Results
TVOC and 2-ethylhexanol concentrations.
Concentrations of TVOC and 2-ethylhexanol
in the chamber air during the PVC challenges
and TVOC during the control tests are shown
in Figure 1. During the control exposure,
2-ethylhexanol concentrations were very low
in the chamber air (≤ 2.4 μg/m3). The correla-
tion between TVOC levels in exposure cham-
ber air and in exhaled breath samples during
the PVC exposure is shown in Figure 2.
Figure 3 shows the correlation between con-
centrations of 2-ethylhexanol in the chamber
and in exhaled breath samples during PVC
exposure. During the PVC exposure tests,
all of the subjects’ exhaled breath samples
contained 2-ethylhexanol, with the concentra-
tions ranging from 1.2 to 9.2 μg/m3 (mean,
5.2 μg/m3).
Symptoms related to the challenge. The
number of subjects reporting respiratory tract
symptoms (e.g., nasal symptoms, cough,
phlegm) was signiﬁcantly higher the morning
after exposure to the PVC material compared
with the morning after control exposure (50%
vs. 0%, respectively; p = 0.029, n = 10).
During PVC exposure, subjects experienced
respiratory tract and conjunctival symptoms
more often than during control challenge, but
the differences were not statistically signiﬁcant
(data not shown). 
Lung functions. Before the PVC challenge,
the baseline values of forced expiratory volume
in 1 sec (FEV1) and forced vital capacity
(FVC) were 109% and 120%, respectively, of
the predicted values. The spirometric values
did not change signiﬁcantly during or after the
PVC challenge, nor did we detect any signiﬁ-
cant differences in lung functions between the
PVC and control exposures. The baseline levels
of lung functions did not differ signiﬁcantly in
subjects with asthma or in smokers (including
current and ex-smokers) compared with the
subjects without asthma or nonsmokers (data
not shown).
PEF values did not change significantly
during or after the challenges, and we found no
significant difference in PEF values between
PVC and control exposures (data not shown).
Exhaled and nasal NO. The exhaled NO
levels did not change significantly during or
after the PVC challenge, and we did not ﬁnd
any significant differences in exhaled NO
concentrations between the PVC and control
exposures (Table 2). Furthermore, there were
no signiﬁcant changes in nasal NO levels dur-
ing or after the PVC exposure or any statisti-
cally signiﬁcant differences between the PVC
and control challenges (Table 3).
Cytokines, NO, and 2-ethylhexanol
in NAL. The levels of cytokines in NAL
(TNF-α, IL-4, IL-6, and IL-12) increased
immediately after exposure to either PVC
ﬂooring or the control material (Table 4); we
found no statistically signiﬁcant differences in
the cytokine concentrations between the chal-
lenges. We did not detect any changes in NO
concentrations of NAL after the PVC expo-
sure nor did we find any statistically signifi-
cant difference when compared to the control
(Table 4).
The cytokine and NO levels in NAL of
samples taken after at least 1 week of vacation
did not differ from the baseline levels before
the exposures. We did not detect the presence
of 2-ethylhexanol in the NAL samples col-
lected after the PVC exposure. 
Cell differential count. Neutrophilic cells
dominated the NAL cell profile both before
and after both exposures. No changes in the
proportions of lymphocytes, neutrophils, or
eosinophils were observed in the NAL after
the challenges. Moreover, we detected no
PVC material challenge
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Table 3. Nasal NO [mean (range), parts per million] before and after exposure to PVC or control material in
the exposure chamber. 
Exposure Before Immediately after 2 hours after Next morning
PVC 151.9 (50.9–213.9) 149.9 (61.5–227.6) 148.4 (60.2–280.7) 157.9 (60.7–321.7)
Control 149.1 (47.1–227.9) 157.9 (49.9–248.8) 160.8 (51.7–279.3) 164.8 (52.0–266.3)
Table 2. Exhaled NO [mean (range), parts per million] before and after exposure to PVC or control material
in the exposure chamber. 
Exposure Before Immediately after 2 hours after Next morning
PVC 23.1 (8.0–66.7)  22.0 (6.4–61.0) 21.8 (8.3–63.0) 26.2 (6.8–68.7)
Control 23.8 (7.8–78.0) 24.9 (7.4–74.2) 25.4 (8.9–75.3) 27.1 (6.8–80.6)differences in the changes in the cell counts
between the PVC and control challenges
(data not shown).
Discussion
In this study, 10 subjects exposed to degraded
PVC flooring material at work were chal-
lenged with PVC exposure under controlled
conditions. This is the first study to expose
subjects to very low concentrations of chemi-
cal emissions similar to those found in indoor
air conditions.
On the morning after the PVC challenge,
the subjects suffered respiratory tract symp-
toms signiﬁcantly more often compared with
the control exposure. This result is in line
with studies in which the subjects experi-
enced similar irritation symptoms during
the exposure to damaged PVC products
(Bornehag et al. 2005b; Wålinder et al. 1999;
Wieslander et al. 1999). According to our
results, even minuscule emissions of degraded
PVC ﬂooring materials that can be found in
indoor air are sufficient to evoke respiratory
tract symptoms.
The PVC ﬂooring material challenge did
not cause any signiﬁcant changes in lung func-
tions, exhaled NO, or nasal NO levels com-
pared with the control test. Moreover, there
were no individual asthmatic reactions, such as
a decrease in FEV1, after these short exposure
times, although half of the subjects had
asthma and their asthma medications had
been withdrawn before the study. In occupa-
tional exposures, the development of asthma
requires long and repeated exposure, as occurs
when workers are exposed to the damaged
PVC material (Tuomainen et al. 2004). There
is strong evidence that damaged PVC prod-
ucts are associated with asthma and atopic dis-
orders (Bornehag et al. 2004; Øie et al. 1997).
The baseline exhaled NO levels were
slightly higher than normal levels deﬁned by
the American Thoracic Society (1999) and the
European Respiratory Society (Kharitonov
et al. 1997); we believe that this is because our
study group included five subjects with
asthma. The baseline nasal NO levels were
also higher than those reported in a previous
study in the same laboratory (Stark et al.
2005). Also, two subjects had very high nasal
NO values, which increased the mean levels of
this small study group.
Cytokine concentrations in NAL increased
after both PVC and control exposures, but we
did not detect any significant differences in
cytokine levels attributable to the active chal-
lenge. Consistently with unaltered nasal NO
levels, the challenge with degraded PVC mate-
rial did not change the NO concentrations in
NAL. Moreover, the cytokine and NO levels
in NAL after the vacation did not differ from
the baseline levels taken before the challenges.
Our timing of the NAL samplings was not
entirely optimal; that is, the subjects reported
a great deal of respiratory tract symptoms on
the morning after PVC exposure, but NAL
samples were not collected at that time. 
We selected ceramic tile as the control
material because it is considered a “clean”
material with very low emissions. However, it
is possible that exposure to ceramic tiles also
evoked inﬂammatory changes that were seen
as increased cytokine levels in NAL. Thus,
another material may be more appropriate for
use as control. On the other hand, it is possi-
ble that PVC exposure does not cause inﬂam-
mation in upper airways that can be detected
as increased cytokine or NO concentrations
in NAL. 
We did not detect any 2-ethylhexanol in
the NAL samples collected after the PVC chal-
lenge. The compound could have evaporated
from the nose before the sampling, which was
performed after the lung function tests and
exhaled and nasal NO measurements. It is also
possible that at least a part of the compound
had been absorbed into the blood. All of the
exhaled breath samples collected during the
PVC carpet exposure contained 2-ethylhexa-
nol. The presence of 2-ethylhexanol in the
exhaled breath is evidence that this compound
is breathed into the lungs, transferred into
blood, and transported to other parts of the
body. It is known to be a specific, biologic
marker for exposure to damaged PVC ﬂooring
material and indicates recent exposure
(Wiglusz et al. 1998). In normal situations
(i.e., when there is no exposure), there is no
2-ethylhexanol present in exhaled breath
(Phillips et al. 1999). Although there were only
10 subjects in this study, the 2-ethylhexanol
concentrations in exhaled breath correlated
well with the levels in chamber air. In spite of
the ventilation of the exposure chamber after
PVC exposures, there were still minimal
concentrations of 2-ethylhexanol in the cham-
ber air at the time we performed the control
tests. These low levels are probably not due to
emissions from ceramic tiles but are probably
connected to the ventilation of the exposure
chamber.
In conclusion, experimental PVC material
exposure evoked respiratory tract symptoms in
exposed subjects but did not cause an immedi-
ate asthma-like reaction. The chamber air expo-
sure test we developed for this study appears to
be very suitable for challenge studies.
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Table 4. Concentrations of cytokines TNF-α, IL-4, IL-6, and IL-12 [mean (range)] and NO [nitrite; mean (range)] in the NAL samples of the study subjects. 
PVC Control
Cytokine/NO After holiday Before  After Before  After
TNF-α (pg/mL) 179.7 (0–1208.8)  152.2 (0–749.0) 267.2 (0–1146.8)  103.9 (0–517.6) 177.5 (0–803.0)
IL-4 (pg/mL) 51.6 (0–379.6)  56.4 (0–276.4) 102.9 (0–529.3)  39.6 (0–234.7)  80.1 (0–533.8)
IL-6 (pg/mL) 76.9 (0.2–572.4)  71.2 (0–383.9)  108.6 (0.1–536.1)  49.3 (0.5–278.4)  106.4 (0–525.9)
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